What does Unicycive do?

Unicycive Therapeutics, Inc. is a clinical-stage biotechnology company based in Los Altos, California, founded in 2016. The company focuses on developing innovative therapies for kidney diseases, particularly hyperphosphatemia and acute kidney injury. Unicycive aims to address unmet medical needs in chronic kidney disease through a streamlined development process, allowing for rapid progression from preclinical stages to commercialization. The company's pipeline includes two lead investigational treatments: Oxylanthanum carbonate, a phosphate-binding agent for hyperphosphatemia in dialysis patients, and UNI-494, a pro-drug of nicorandil for acute kidney injury. Unicycive collaborates with various partners, including Shilpa Medicare Ltd. and Syneos Health LLC, to advance its research and development efforts. With a dedicated team and a focus on kidney health, Unicycive is committed to making a positive impact in the lives of patients with kidney-related conditions.